AR125857A1 - ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS - Google Patents
ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍASInfo
- Publication number
- AR125857A1 AR125857A1 ARP220101267A ARP220101267A AR125857A1 AR 125857 A1 AR125857 A1 AR 125857A1 AR P220101267 A ARP220101267 A AR P220101267A AR P220101267 A ARP220101267 A AR P220101267A AR 125857 A1 AR125857 A1 AR 125857A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- heavy chain
- synuclein
- seq
- set forth
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 5
- 102000023732 binding proteins Human genes 0.000 abstract 3
- 108091008324 binding proteins Proteins 0.000 abstract 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación proporciona proteínas de unión aisladas, tales como anticuerpos humanizados y fragmentos de unión a antígenos de los mismos que se dirigen a la alfa-sinucleína, incluyendo proteínas de unión aisladas multiespecíficas que se dirigen tanto a la a-sinucleína como al receptor del factor de crecimiento similar a la insulina 1. También se proporcionan métodos de uso de las proteínas de unión para tratar las a-sinucleinopatías. Reivindicación 1: Un anticuerpo humanizado o fragmento de unión a antígenos del mismo que se une a la a-sinucleína humana, en donde el anticuerpo o fragmento de unión a antígenos comprende: una región variable de cadena pesada (VH) que comprende (i) regiones de cadena pesada que determinan complementariedad (CDR) 1-3 que se establecen en las SEQ ID Nº 33 - 35, respectivamente y (ii) regiones marco de cadena pesada (FR) 1, 2 y/o 3 de un gen VH1-02 humano; y una región variable de cadena ligera (VL) que comprende las CDR1-3 de cadena ligera que se establecen en SEQ ID NO: 36 - 38, respectivamente. Reivindicación 4: Un anticuerpo humanizado o fragmento de unión a antígenos del mismo que se une a la a-sinucleína humana, en donde el anticuerpo o fragmento de unión a antígenos comprende: una región variable de cadena pesada (VH) que comprende las regiones de cadena pesada que determinan complementariedad (CDR) 1-3 que se establecen en las SEQ ID Nº 64 - 66, respectivamente; y una región variable de cadena ligera (VL) que comprende las CDR1-3 de cadena ligera que se establecen en SEQ ID Nº 67 - 69, respectivamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210061407 | 2021-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125857A1 true AR125857A1 (es) | 2023-08-16 |
Family
ID=84028418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101267A AR125857A1 (es) | 2021-05-12 | 2022-05-12 | ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220380446A1 (es) |
| EP (1) | EP4340881A4 (es) |
| JP (1) | JP2024520905A (es) |
| KR (1) | KR20240031229A (es) |
| CN (1) | CN117858721A (es) |
| AR (1) | AR125857A1 (es) |
| AU (1) | AU2022271678A1 (es) |
| BR (1) | BR112023023284A2 (es) |
| CA (1) | CA3219659A1 (es) |
| CO (1) | CO2023015859A2 (es) |
| IL (1) | IL308393A (es) |
| MX (1) | MX2023013392A (es) |
| TW (1) | TW202309076A (es) |
| WO (1) | WO2022238961A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110494445B (zh) | 2017-01-06 | 2023-10-20 | Abl生物公司 | 抗α-SYN抗体及其用途 |
| CA3085572A1 (en) | 2017-12-14 | 2019-06-20 | Abl Bio Inc. | Bispecific antibody to a-syn/igf1r and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6342333B2 (ja) * | 2012-01-27 | 2018-06-13 | プロセナ バイオサイエンシーズ リミテッド | α−シヌクレインを認識するヒト化抗体 |
| EP3567054A4 (en) * | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| MX2020004674A (es) * | 2017-11-17 | 2020-08-13 | Abl Bio Inc | Anticuerpos contra alfa-sinucleina y usos de los mismos. |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| EP3985022A4 (en) * | 2019-06-14 | 2023-08-02 | ABL Bio, Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE |
-
2022
- 2022-05-12 WO PCT/IB2022/054445 patent/WO2022238961A1/en not_active Ceased
- 2022-05-12 CA CA3219659A patent/CA3219659A1/en active Pending
- 2022-05-12 AU AU2022271678A patent/AU2022271678A1/en active Pending
- 2022-05-12 BR BR112023023284A patent/BR112023023284A2/pt unknown
- 2022-05-12 MX MX2023013392A patent/MX2023013392A/es unknown
- 2022-05-12 US US17/743,177 patent/US20220380446A1/en active Pending
- 2022-05-12 TW TW111117860A patent/TW202309076A/zh unknown
- 2022-05-12 CN CN202280034495.2A patent/CN117858721A/zh active Pending
- 2022-05-12 JP JP2023569822A patent/JP2024520905A/ja active Pending
- 2022-05-12 KR KR1020237042723A patent/KR20240031229A/ko active Pending
- 2022-05-12 AR ARP220101267A patent/AR125857A1/es unknown
- 2022-05-12 IL IL308393A patent/IL308393A/en unknown
- 2022-05-12 EP EP22806958.9A patent/EP4340881A4/en active Pending
-
2023
- 2023-11-22 CO CONC2023/0015859A patent/CO2023015859A2/es unknown
-
2024
- 2024-11-06 US US18/938,970 patent/US20250059266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL308393A (en) | 2024-01-01 |
| US20250059266A1 (en) | 2025-02-20 |
| KR20240031229A (ko) | 2024-03-07 |
| CO2023015859A2 (es) | 2024-02-26 |
| AU2022271678A1 (en) | 2024-01-04 |
| MX2023013392A (es) | 2024-02-15 |
| CA3219659A1 (en) | 2022-11-17 |
| JP2024520905A (ja) | 2024-05-27 |
| WO2022238961A1 (en) | 2022-11-17 |
| EP4340881A1 (en) | 2024-03-27 |
| BR112023023284A2 (pt) | 2024-01-30 |
| EP4340881A4 (en) | 2025-05-14 |
| TW202309076A (zh) | 2023-03-01 |
| US20220380446A1 (en) | 2022-12-01 |
| CN117858721A (zh) | 2024-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| CO2021006248A2 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| AR125857A1 (es) | ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| RU2012113554A (ru) | Антитела к рецепту глюкагана и их использование | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| MX2024015285A (es) | Anticuerpos anti-egfr/met y usos de los mismos | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| UY38807A (es) | Proteínas de unión a antígeno anti-il13 | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 | |
| MX2025003940A (es) | Métodos para tratar cáncer con anticuerpos biespecíficos egfr x cd28 solos o en combinación con anticuerpos anti-pd-1 | |
| MX2022002363A (es) | Sistema receptor de antígeno quimérico y usos de este. | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR130641A1 (es) | Anticuerpos anti-cd28 | |
| AR131055A1 (es) | Anticuerpos anti-papp-a y métodos de uso de estos | |
| AR126971A1 (es) | Composiciones y métodos para tratar el síndrome de qt largo | |
| PE20250796A1 (es) | Moleculas de union al antigeno anti-steap1 y sus usos | |
| EA202191367A1 (ru) | Антитела к nkg2a и варианты их применения | |
| AR130865A1 (es) | Agentes de unión de msln y cd3 y métodos de uso de estos |